Menu
Recruiting NCT06818396

Analgesic Efficacy of Fascia Iliaca Compartment Block Compared With Intrathecal Nalbuphine for Hip Surgery Under Spinal Anesthesia

No phase Interventional Postoperative Pain

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: US-guided fascia iliaca compartment block (FICB) and spinal anesthesia, Intrathecal nalbuphine and spinal anesthesia, Spinal anesthesia.
Who it may be relevant to
Registry conditions: Postoperative Pain. Basic parameters: from 21 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

Analgesic Efficacy of Fascia Iliaca Compartment Block Compared With Intrathecal Nalbuphine for Hip Surgery Under Spinal Anesthesia: a Randomized Controlled Trial

Overview

It is already known that fascia iliaca compartment block and intrathecal nalbuphine are very effective ways in postoperative pain control in patients having hip surgeries.

Interventions

  • Other US-guided fascia iliaca compartment block (FICB) and spinal anesthesia
    US-guided fascia iliaca compartment block (FICB) and spinal anesthesia
  • Drug Intrathecal nalbuphine and spinal anesthesia
    intrathecal nalbuphine and spinal anesthesia
  • Other Spinal anesthesia
    Spinal anesthesia

Primary outcome measures

  • Time to first rescue analgesia (minutes). [Time frame: in the first 24 hours after surgery]

Eligibility criteria

Inclusion criteria

  • American Society of Anesthesiologists (ASA) score (ASA I- ASA II).
  • Age ≥ 21years.
  • Body mass index < 35 kg/m2

Exclusion criteria

  • Patient's refusal.
  • Known coagulopathy.
  • Known peripheral neuropathy or neurological deficits.
  • Known allergy to study drugs

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Prevention

Study locations

Egypt · 1 center
  • Ain-Shams University Hospitals — Cairo

Identifiers

NCT: NCT06818396 · FMASU-MS 72 / 2025

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗